Latest From kaleo Inc.
The acting commissioner's statement is intended to clarify "persistent misunderstanding" about the label for the opioid overdose rescue medication's injectable formulation.
Opioid overdose treatments containing naloxone or nalmefene are now eligible for expedited ANDA review in a bid by the FDA to improve patient access.
In announcing expedited assessments for new naloxone ANDAs, the agency also offers guidance to sponsors of discontinued products considering a return to marketing.
Development of the model DFLs was a first for agency. The project was "part of our broader commitment to addressing the opioid crisis" and should help sponsors with potential naloxone OTC switch NDAs, says Commissioner Scott Gottlieb.
- Medical Devices
- Drug Delivery
- Therapeutic Areas
- Immune Disorders
- Intelliject Inc.
- North America
- Parent & Subsidiaries
- kaleo Inc.
- Senior Management
T. Spencer Williamson, IV, Pres. & CEO
Christopher T Schools, CFO
Kristopher D Ford, VP, Bus. Dev.
Eric Edwards, MD, PhD, VP, R&D & CMO
- Contact Info
Phone: (804) 545-6360
111 Virginia St.
Richmond, VA 23219
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.